GreenLight Biosciences Holdings (GRNA) Bundle
A Brief History of GreenLight Biosciences Holdings (GRNA)
Formation and Initial Focus
GreenLight Biosciences Holdings, Inc. was founded in 2008, focusing on the development of RNA-based biotechnologies. Its primary objective was to leverage RNA interference to create more effective agricultural products, particularly in pest management and crop enhancement.
IPO and Financials
GreenLight Biosciences went public on the NASDAQ under the ticker symbol GRNA on October 12, 2020. The IPO raised approximately $70 million by offering 6.7 million shares at a price of $10.50 each.
Key Developments
In 2021, the company announced several collaborations and partnerships aimed at developing sustainable agricultural solutions. In January 2021, GreenLight received a $12 million investment from the Bill & Melinda Gates Foundation to support the development of RNAi-based traits for agriculture.
Market Performance
As of September 30, 2023, GreenLight Biosciences had a market capitalization of approximately $300 million. The stock price fluctuated significantly, with a 52-week range between $0.50 and $3.50.
Product Pipeline
| Product | Target Crop | Stage of Development | Expected Launch |
|---|---|---|---|
| GLB-101 | Corn | Field Trials | 2024 |
| GLB-202 | Soybean | Regulatory Approval | 2025 |
| GLB-303 | Cotton | Research Phase | 2026 |
Financial Performance
For the fiscal year ending December 31, 2022, GreenLight reported revenues of $5.2 million, a 30% increase from $4 million in 2021. However, the company also recorded a net loss of $34 million, compared to a net loss of $28 million in the previous year.
Research and Development Expenditure
In 2022, GreenLight Biosciences allocated approximately $20 million to research and development, representing about 38% of total expenditures.
Regulatory Milestones
- Received regulatory approval for its first RNA product in Canada in March 2023.
- Filed for regulatory review with the EPA in September 2023.
- Initiated discussions with EU regulatory bodies regarding product approval in October 2023.
Strategic Partnerships
GreenLight has formed strategic partnerships with several agricultural companies aimed at expanding its market reach:
- Bayer Crop Science
- Corteva Agriscience
- Syngenta
Future Outlook
Analysts project that the global RNA-based agricultural market will reach $13 billion by 2026, spurring growth opportunities for GreenLight Biosciences. The company’s focus on sustainable and environmentally friendly agricultural solutions positions it well in a competitive market.
A Who Owns GreenLight Biosciences Holdings (GRNA)
Current Shareholders
As of the latest available data, the ownership structure of GreenLight Biosciences Holdings (GRNA) comprises both institutional and retail investors. Below is a breakdown of significant shareholders:
| Shareholder Type | Holder Name | Percentage Ownership | Number of Shares |
|---|---|---|---|
| Institutional Investor | Vanguard Group Inc. | 9.06% | 2,115,000 |
| Institutional Investor | BlackRock Inc. | 7.89% | 1,850,000 |
| Institutional Investor | Citadel Advisors LLC | 5.76% | 1,350,000 |
| Retail Investor | Individual Shareholders | 25% | 5,850,000 |
| Private Equity | GreenLight Biosciences Holdings | 52.29% | 12,180,000 |
Insider Ownership
Insider ownership is a significant aspect of GreenLight Biosciences' structure, reflecting confidence in the company's future. The following individuals hold key insider positions:
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Anders J. R. M. Krogh | CEO | 2,000,000 | 8.56% |
| Michael W. McKinnon | CFO | 1,000,000 | 4.28% |
| Raffi T. K. Ota | Director | 750,000 | 3.20% |
Recent Stock Performance
GreenLight Biosciences Holdings has shown varied stock performance in recent months. Key metrics include:
| Metric | Value |
|---|---|
| Current Stock Price | $1.75 |
| Market Capitalization | $410 million |
| 52-Week High | $5.00 |
| 52-Week Low | $1.20 |
| Year-to-Date Performance | -30% |
Future Capital Structure
Looking ahead, GreenLight Biosciences is expected to explore further financing options, including potential equity raises or partnerships. Current liquidity status is summarized as follows:
| Metric | Value |
|---|---|
| Cash on Hand | $50 million |
| Total Debt | $20 million |
| Debt-to-Equity Ratio | 0.25 |
GreenLight Biosciences Holdings (GRNA) Mission Statement
Corporate Mission
The mission of GreenLight Biosciences Holdings (GRNA) is to leverage its proprietary RNA platform to enhance agriculture and improve global food security while promoting sustainable practices. The company aims to develop innovative, environmentally friendly solutions that meet the growing demand for food production.
Commitment to Sustainability
GreenLight emphasizes a commitment to sustainability, focusing on:
- Reducing the reliance on chemical pesticides and fertilizers.
- Enhancing crop resilience against pests and diseases.
- Developing biopesticides that are safe for beneficial insects and humans.
Recent Financial Performance
As of the second quarter of 2023, GreenLight Biosciences reported the following financial data:
| Metric | Value |
|---|---|
| Total Revenue | $1.5 million |
| Net Loss | ($8.4 million) |
| Operating Expenses | $9.6 million |
| Cash and Cash Equivalents | $22.3 million |
| Total Assets | $35.7 million |
Technology and Innovation
GreenLight’s innovative technology is rooted in RNA (Ribonucleic Acid) biology, which allows for:
- Targeted pest control through gene silencing.
- -Developing RNA-based products that have minimal environmental impact.
- Addressing critical agricultural challenges with precision.
Market Potential
The global agricultural biopesticide market size was valued at approximately $4.9 billion in 2021 and is projected to expand at a CAGR of 14.3% from 2022 to 2030.
Partnerships and Collaborations
GreenLight has established strategic partnerships to enhance its product development and market reach:
- Collaboration with major agricultural firms to integrate RNA technology into existing crop protection systems.
- Research partnerships with universities to advance RNA science.
Future Goals
GreenLight has set ambitious goals for the coming years, focusing on:
- Expanding its product pipeline in the biopesticide sector.
- Increasing market penetration across various crops and regions.
- Achieving commercial viability of its RNA-based solutions by 2025.
Conclusion
GreenLight Biosciences is positioning itself as a leader in the field of sustainable agriculture through its innovative RNA technology, targeting critical issues facing food production and environmental sustainability.
How GreenLight Biosciences Holdings (GRNA) Works
Business Model
GreenLight Biosciences Holdings operates primarily in the biotechnology sector, focusing on using RNA interference (RNAi) technology for agricultural solutions. The company's objective is to develop sustainable agricultural products such as biopesticides and RNA-based treatments for various crops.
Key Technologies
The primary technology employed by GreenLight is RNAi, which is designed to target and silence specific genes in pests and pathogens. This technique allows for enhanced efficacy in crop protection compared to traditional methods.
Financial Overview
| Year | Revenue ($ Million) | Operating Expenses ($ Million) | Net Income ($ Million) | Total Assets ($ Million) | Total Liabilities ($ Million) |
|---|---|---|---|---|---|
| 2021 | 2.1 | 45.6 | -43.5 | 32.4 | 20.1 |
| 2022 | 3.8 | 56.3 | -52.5 | 29.8 | 27.9 |
| 2023 | 5.0 | 60.5 | -55.5 | 30.1 | 28.3 |
Research and Development
GreenLight Biosciences allocates a significant portion of its budget to R&D to innovate and improve its product offerings. In 2022, R&D expenditures amounted to approximately $30 million, representing about 53% of total operating expenses.
Market Applications
- Agricultural Pest Control
- Crop Yield Improvement
- Disease Resistance
- Environmental Sustainability
Partnerships and Collaborations
GreenLight has established partnerships with various agricultural corporations and research institutions to advance its technology and expand its market reach. Notable collaborations include partnerships with major companies like BASF and Syngenta.
Market Position and Competitors
In the evolving market of sustainable agriculture, GreenLight competes with other biotechnology firms, including:
- Intrexon Corporation
- AgBiome
- Corteva Agriscience
- Bayer Crop Science
Stock Information
As of October 2023, GreenLight Biosciences is publicly traded on the NASDAQ under the ticker symbol GRNA. The stock price has fluctuated significantly over the past year with market capitalization standing at approximately $100 million.
Funding and Investment
GreenLight has successfully raised capital through various funding rounds, including:
- $15 million in a Series B round in 2021
- $20 million in a Series C round in 2022
- $10 million through public offerings in 2023
Future Prospects
GreenLight's growth strategy involves expanding its product portfolio and increasing its market penetration. The company aims to increase revenues to over $15 million by 2025, focusing on launching new RNA-based products and enhancing its customer base.
How GreenLight Biosciences Holdings (GRNA) Makes Money
Revenue Streams
GreenLight Biosciences generates revenue through several key avenues:
- Sale of RNA-based agricultural products
- Partnerships and collaborations with agricultural companies
- Grants and funding from governmental and private organizations
RNA-Based Agricultural Products
GreenLight specializes in developing and commercializing RNA-based products for agriculture, which includes:
- RNA molecules that target pests and diseases in crops
- RNA biopesticides
As of Q3 2022, GreenLight reported commercial agreements valued at approximately $30 million over multiple years.
Partnerships and Collaborations
Strategic collaborations play a crucial role in GreenLight's financial structure. They include:
- Collaboration with major agricultural firms like Syngenta and Bayer
- Long-term contracts with regional agricultural distributors
In total, these partnerships have the potential to yield revenues of up to $100 million by 2025 based on projected market growth.
Funding and Grants
GreenLight has secured substantial funding from various sources:
- Received a grant of $15 million from the U.S. Department of Agriculture for research and development
- Raised $60 million through private equity financing in 2021
Financial Performance Metrics
The financial performance of GreenLight can be summarized with the following metrics:
| Metric | Amount |
|---|---|
| Total Revenue (2022) | $5 million |
| Net Loss (2022) | $(23 million) |
| Cash and Cash Equivalents (Q3 2022) | $40 million |
| Market Capitalization (as of October 2023) | Approximately $200 million |
Market Trends and Growth Opportunities
The growing demand for sustainable agricultural practices and biopesticides presents significant opportunities for GreenLight:
- Increasing global market size for biopesticides projected to reach $10 billion by 2025
- Rising consumer demand for food safety and reduced chemical residues
Intellectual Property and Innovation
GreenLight invests heavily in R&D, supporting its innovative pipeline:
- Possesses over 50 patents related to RNA technology in agriculture
- Annual R&D expenditure estimated at $20 million
These factors collectively contribute to the long-term profitability and revenue potential for GreenLight Biosciences Holdings (GRNA).
GreenLight Biosciences Holdings (GRNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support